mexiletine has been researched along with Myocardial Ischemia in 12 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 7.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| "Mexiletine's TTI was found to be less than two, which accords with its clinical therapeutic index." | 5.56 | Characterisation of mexiletine's translational therapeutic index for suppression of ischaemia-induced ventricular fibrillation in the rat isolated heart. ( Ahdi, N; Curtis, MJ; Hesketh, LM; Lytra, G; Munro, JS; Qazimi, P; Ranadive, NN; Wilder, CDE, 2020) |
| "We enrolled all consecutive patients with unsuccessful/not feasible catheter ablation and ineffective/contraindicated amiodarone or beta-blockers, which started the mexiletine treatment for refractory ventricular tachycardia (VT) or ventricular fibrillation (VF) between January 2010 and January 2020." | 4.12 | Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study. ( Bilato, C; Cavedon, S; Mecenero, A; Mugnai, G; Paolini, C; Perrone, C, 2022) |
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 3.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| "Mexiletine has limited efficacy in the treatment of recurrent VT despite high-dose amiodarone therapy, in patients with ischemic heart disease." | 2.87 | Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. ( Deyell, MW; Doucette, S; Essebag, V; Gardner, M; Gray, C; Healey, JS; Hruczkowski, T; Leong-Sit, P; Nault, I; Nery, PB; Parkash, R; Rivard, L; Sapp, JL; Steinberg, C; Sterns, LD, 2018) |
| "Mexiletine's TTI was found to be less than two, which accords with its clinical therapeutic index." | 1.56 | Characterisation of mexiletine's translational therapeutic index for suppression of ischaemia-induced ventricular fibrillation in the rat isolated heart. ( Ahdi, N; Curtis, MJ; Hesketh, LM; Lytra, G; Munro, JS; Qazimi, P; Ranadive, NN; Wilder, CDE, 2020) |
| "Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in isolation and in combination with other class III medications." | 1.37 | Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. ( Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hesketh, LM | 1 |
| Wilder, CDE | 1 |
| Ranadive, NN | 1 |
| Lytra, G | 1 |
| Qazimi, P | 1 |
| Munro, JS | 1 |
| Ahdi, N | 1 |
| Curtis, MJ | 1 |
| Mugnai, G | 1 |
| Paolini, C | 1 |
| Cavedon, S | 1 |
| Mecenero, A | 1 |
| Perrone, C | 1 |
| Bilato, C | 1 |
| Deyell, MW | 1 |
| Steinberg, C | 1 |
| Doucette, S | 1 |
| Parkash, R | 1 |
| Nault, I | 1 |
| Gray, C | 1 |
| Essebag, V | 1 |
| Gardner, M | 1 |
| Sterns, LD | 1 |
| Healey, JS | 1 |
| Hruczkowski, T | 1 |
| Rivard, L | 1 |
| Leong-Sit, P | 1 |
| Nery, PB | 1 |
| Sapp, JL | 1 |
| Bunch, TJ | 1 |
| Mahapatra, S | 1 |
| Murdock, D | 1 |
| Molden, J | 1 |
| Weiss, JP | 1 |
| May, HT | 1 |
| Bair, TL | 1 |
| Mader, KM | 1 |
| Crandall, BG | 1 |
| Day, JD | 1 |
| Osborn, JS | 1 |
| Muhlestein, JB | 1 |
| Lappe, DL | 1 |
| Anderson, JL | 1 |
| Niwano, S | 2 |
| Inuo, K | 2 |
| Morohoshi, Y | 2 |
| Nakayama, S | 2 |
| Yuge, M | 1 |
| Imaki, R | 1 |
| Izumi, T | 2 |
| Liu, KX | 1 |
| Yamamoto, F | 1 |
| Yamamoto, H | 1 |
| Wang, T | 1 |
| Zhu, Z | 1 |
| Xu, R | 1 |
| Zhang, S | 1 |
| Kamiyama, T | 1 |
| Tanonaka, K | 1 |
| Harada, H | 1 |
| Nakai, K | 1 |
| Takeo, S | 1 |
| Komori, S | 1 |
| Sawanobori, T | 1 |
| Tamura, K | 1 |
| Kane, KA | 1 |
| Parratt, JR | 1 |
| Mondillo, S | 1 |
| Faglia, S | 1 |
| D'Aprile, N | 1 |
| Mangiacotti, L | 1 |
| Campolo, MA | 1 |
| Agricola, E | 1 |
| Palazzuoli, V | 1 |
| Murakami, M | 1 |
| Kinukawa, M | 1 |
| Kanazawa, T | 1 |
| Maruyama, K | 1 |
| Miyagi, M | 1 |
| Miyata, H | 1 |
| Ujiie, A | 1 |
| Li, H | 1 |
| Xu, KY | 1 |
| Zhou, L | 1 |
| Kalai, T | 1 |
| Zweier, JL | 1 |
| Hideg, K | 1 |
| Kuppusamy, P | 1 |
| Ikeda, K | 1 |
| Kojima, J | 1 |
| Saito, J | 1 |
| Masuda, T | 1 |
2 trials available for mexiletine and Myocardial Ischemia
| Article | Year |
|---|---|
Mexiletine or catheter ablation after amiodarone failure in the VANISH trial.
Topics: Action Potentials; Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Drug Substitution; F | 2018 |
[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Drug Sy | 1995 |
10 other studies available for mexiletine and Myocardial Ischemia
| Article | Year |
|---|---|
Characterisation of mexiletine's translational therapeutic index for suppression of ischaemia-induced ventricular fibrillation in the rat isolated heart.
Topics: Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Electrocardiography; Heart; Male; | 2020 |
Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Coronary Artery Disease | 2022 |
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Def | 2011 |
Mexiletine protects myocardium during acute ischemia by opening sarcolemmal K-ATP channel: studies in closed-chest acute ischemia model in rabbits.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; ATP-Binding Cassette Transporters; Disease Models, A | 2004 |
The effects of Na movement on surgical myocardial protection: the role of the Na+-H+ exchange system and Na-channel in the development of ischemia and reperfusion injury.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Cardiac Output; Cardioplegic Solutions; Guani | 2007 |
Mexiletine and lidocaine reduce post-ischemic functional and biochemical dysfunction of perfused hearts.
Topics: Adenosine Triphosphate; Animals; Calcium; Creatine Kinase; Lidocaine; Mexiletine; Myocardial Contrac | 1995 |
Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Topics: Amino Alcohols; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Dise | 1994 |
Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclooxygenase | 1996 |
A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Binding, Competitive; Coronary Circulation; Dose-Resp | 2000 |
Cardioprotective effect of mexiletine in acute myocardial ischemia tudies in the rabbit closed chest ischemia mode.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Angiography; Coronary V | 2002 |